Author:
Jatin Vyas (US)
Abstract:
Inhibition of Bruton’s tyrosine kinase (BTK) through covalent modifications of its active site (e.g., ibrutinib [IBT]) is the preferred treatment for chronic B-lymphocyte leukemia and mantle cell lymphoma. However, IBT-treated patients are highly susceptible to invasive fungal infections, including invasive aspergillosis, though the mechanism is poorly understood. Neutrophils are the primary line of defense against invasive fungal infections; therefore, we examined the impact of IBT on primary human neutrophil effector activity against Aspergillus fumigatus. IBT significantly impaired the ability of neutrophils to kill A. fumigatus and potently inhibited reactive oxygen species (ROS) production, chemotaxis, and phagocytosis. Importantly, exogenous TNFα fully compensated for these IBT-associated defects. TNFα also restored the effector activity of neutrophils treated with acalabrutinib and zanubrutinib, newer generation BTK inhibitors. Blocking TNFα with infliximab did not impact ROS production in healthy neutrophils but prevented exogenous TNFα from rescuing the phenotype of IBT-treated neutrophils. The restorative capacity of TNFα was independent of transcription, as ROS production was rescued even after using a transcription inhibitor on IBT-treated neutrophils. Moreover, the addition of TNFα immediately rescued ROS production in IBT-treated neutrophils indicating that TNFα worked through a BTK-independent signaling pathway. Finally, TNFα restored the effector activity of primary neutrophils from patients on IBT therapy, recapitulating our in vitro findings. Altogether, our data indicate that TNFα rescues the block in antifungal immunity imposed by the inhibition of BTK in primary human neutrophils.
Abstract Number: 61
Conference Year: 2024
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Khostelidi S1,2, Borzova Y2., Shadrivova O1, Desyatik E2., Karpishchenko S3 ., Charushin A.O4., Avdeenko Y2., Bogomolova T2., Ignatieva S2., Taraskina A.2, Burova S.A5., Vasylieva N.V.2
2024
40
n/a
-
v
Balogun O.J, Ajibola O.O.E., Oladele R.O., Fashanu T.A, Gangneux J.P., Denning D.W
2024
39
n/a
-
v
Su Chen, Ruoyu Li, Wei Chen, Zhe Wan, Wei Liu
2024
38
n/a
-
v
K.A. Marr,1,2 N. Permpalung,1 S. Rajack,1 K. Datta,1 D. Ostrander,1 J.F. Staab,1 K. Witwer,1 I. Baburina,2 D. Neitzey,2 P. X. Marques,2 R. Aerts,3 J. Maertens,3 D. Sheppard,4 J.R. Wingard,5 and S. X. Zhang,1
2024
37
n/a
-
v
Walshe. K, Dwyer. M and Doyle.S (IE)
2024
36
n/a
-
v
Jiří Houšť1, Radim Dobiáš2, Dominika Luptáková1, Andrea Palyzová1, Tomáš Pluháček1, Milan Navrátil3, David A. Stevens4, Rutuja H. Patil1, and Vladimír Havlíček1
2024
35
n/a
-
v
Mragnayani Pandey (IN), Immaculata Xess, Janya Sachdev, Neha Sharad, Sonakshi Gupta, Gagandeep Singh, Renu Kumari Yadav, Bhaskar Rana, Stephen Raj, M Nizam Ahmad, Neha Nityadarshini, Upendra Baitha, Manish Soneja, Shalimar, Bindu Prakash, Kapil Sikka, Purva Mathur, Viveka P Jyotsna, Rakesh Kumar, Naveet Wig, Ashutosh Biswas, Alok Thakar,
2024
34
n/a
-
v
Vladimir Havliecek1,2, R Dobias3,4, D Luptakova1, R Patil1,2, J Houst1,2, D Stevens5,6, M Petrik7, A Palyzova1, T Pluhacek1,2
2024
33
n/a
-
v
Sebastien Imbert (FR)
2024
32
n/a
-
v
Inderpaul Singh Sehgal,Valliappan Muthu ,aShivaprakash M Rudramurthy dArunaloke Chakrabarti Ritesh Agarwal
2024
31
n/a